These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 27018481

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I.
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [Abstract] [Full Text] [Related]

  • 23. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
    Piu C, Ibba G, Bertoli D, Capra R, Uleri E, Serra C, Imberti L, Dolei A.
    J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472
    [Abstract] [Full Text] [Related]

  • 24. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
    Schwab N, Schneider-Hohendorf T, Hoyt T, Gross CC, Meuth SG, Klotz L, Foley JF, Wiendl H.
    Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
    [Abstract] [Full Text] [Related]

  • 25. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
    Dominguez-Mozo MI, Rus M, Santiago JL, Izquierdo G, Casanova I, Galan V, Garcia-Martinez MA, Arias-Leal AM, García-Montojo M, Pérez-Pérez S, Arroyo R, Alvarez-Lafuente R.
    Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
    [Abstract] [Full Text] [Related]

  • 26. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Incidence of seroconversion and sero-reversion in patients with multiple sclerosis (MS) who had been treated with natalizumab: A systematic review and meta-analysis.
    Azimi A, Hanaei S, Sahraian MA, Mohammadifar M, Ramagopalan SV, Ghajarzadeh M.
    J Clin Neurosci; 2020 Jan; 71():129-134. PubMed ID: 31558363
    [Abstract] [Full Text] [Related]

  • 29. JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.
    Delbue S, Elia F, Carloni C, Pecchenini V, Franciotta D, Gastaldi M, Colombo E, Signorini L, Carluccio S, Bellizzi A, Bergamaschi R, Ferrante P.
    J Neurovirol; 2015 Dec; 21(6):645-52. PubMed ID: 25052191
    [Abstract] [Full Text] [Related]

  • 30. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
    Reuwer AQ, Heron M, van der Dussen D, Schneider-Hohendorf T, Murk JL.
    Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
    [Abstract] [Full Text] [Related]

  • 31. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
    Schweitzer F, Ladwig A, Opala S, Laurent S, Schroeter M, Goelz S, Fink GR, Wieland U, Silling S, Warnke C.
    Mult Scler Relat Disord; 2024 Jul; 87():105664. PubMed ID: 38735204
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
    Werner MH, Huang D.
    J Neurovirol; 2016 Dec; 22(6):871-875. PubMed ID: 27198748
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Anti-JC virus seroprevalence in a Finnish MS cohort.
    Kolasa M, Hagman S, Verkkoniemi-Ahola A, Airas L, Koivisto K, Elovaara I.
    Acta Neurol Scand; 2016 May; 133(5):391-7. PubMed ID: 26347001
    [Abstract] [Full Text] [Related]

  • 36. Rates of John Cunningham virus seroconversion greatly reduced in natalizumab-treated patients during COVID-19-related lockdowns.
    Dwyer C, Sharmin S, Kalincik T.
    Eur J Neurol; 2024 Jan; 31(1):e16059. PubMed ID: 37707348
    [Abstract] [Full Text] [Related]

  • 37. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
    Fabis-Pedrini MJ, Xu W, Burton J, Carroll WM, Kermode AG.
    J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
    [Abstract] [Full Text] [Related]

  • 38. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
    Yap SM, McGuigan C.
    Mult Scler; 2017 May; 23(6):765-767. PubMed ID: 28287039
    [No Abstract] [Full Text] [Related]

  • 39. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, de Vos M, Warnke C, Uitdehaag BMJ, Barkhof F, Killestein J, Wattjes MP.
    JAMA Neurol; 2018 Jul 01; 75(7):827-833. PubMed ID: 29532061
    [Abstract] [Full Text] [Related]

  • 40. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.
    Bellaguarda E, Keyashian K, Pekow J, Rubin DT, Cohen RD, Sakuraba A.
    Clin Gastroenterol Hepatol; 2015 Nov 01; 13(11):1919-25. PubMed ID: 26001336
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.